Wei AH, et al. - In older adults (60 years or older) with previously untreated acute myeloid leukemia (AML) ineligible for intensive chemotherapy, the safety and preliminary effectiveness of venetoclax (a selective B-cell leukemia/lymphoma-2 inhibitor) together with low-dose cytarabine (LDAC) was assessed in an international phase Ib/II study. This study included 82 patients who were administered the recommended phase II dose: venetoclax 600 mg per day orally in 28-day cycles, with LDAC (20 mg/m²per day) given subcutaneously on days 1 to 10. In this study population, rapid and durable remissions were produced by venetoclax plus LDAC, which also displayed a manageable safety profile. In addition, high remission rate and low early mortality, as well as rapid and durable remission, were observed in relation to venetoclax plus LDAC, and thus, this combination affords an attractive and novel treatment option for such a patient populace.